Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986147 · 1 trial · 1 indication
Adverse event (AE)
| Arm | Type | Description |
|---|---|---|
| A1: BMS-986147 or Placebo matching BMS-986147 | PLACEBO_COMPARATOR | Single oral dose as specified |
| A2: BMS-986147 or Placebo matching BMS-986147 | PLACEBO_COMPARATOR | Single oral dose as specified |
| A3: BMS-986147 or Placebo matching BMS-986147 | PLACEBO_COMPARATOR | Single oral dose as specified |
| B1: BMS-986147 or Placebo matching BMS-986147 | ACTIVE_COMPARATOR | Daily oral dose as specified |
| B2: BMS-986147 or Placebo matching BMS-986147 | ACTIVE_COMPARATOR | Daily oral dose as specified |
| Name | Type | Description |
|---|---|---|
| BMS-986147 | DRUG | - |
| Placebo matching BMS-986147 | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy men and women, ages 18 to 45 years * Subjects must not have clinically significant deviation from normal: medical history, physical examination, ECGs and laboratory e...
BMS-986147 is an investigational small molecule developed by Bristol-Myers Squibb Company (NYSE: BMY). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The compound remains in early clinical development, and no approved indication has been disclosed for it.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of BMS-986147. The company sponsored the Phase 1 study of the compound conducted in the United States.
BMS-986147 is in Phase 1 development. Its only recorded clinical trial, NCT02293629, was a Phase 1 study that has been completed. The drug is investigational and has not been approved for any indication.
BMS-986147 has been evaluated in one clinical trial, NCT02293629, titled a single and multiple ascending dose study to evaluate safety, pharmacokinetics, and target engagement in healthy subjects. The Phase 1 trial enrolled 8 participants in the United States and is completed.
The Phase 1 trial NCT02293629 was a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of BMS-986147. It enrolled 8 healthy adult volunteers of any sex, aged 18 years and older, at sites in the United States, and assessed safety, pharmacokinetics, and target engagement.